On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable 1 for 3.15 entitlement offer (Entitlement Offer).
Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately $7.4 million, and announced the completion of the Retail Entitlement Offer on 23 March 2022, which raised approximately $4.3 million.
For more information, download the attached PDF.
Download this document
